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point demonstrated that t(11;18)(q21;q21) leads to the
fusion of the IAP2 gene to the MALT1 gene (Akagi et
al., 1999; Dierlamm et al., 1999; Morgan et al., 1999).
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resembles the catalytic domain of caspases at its C620 University Avenue
terminus (Uren et al., 2000). Because of this “caspase-Toronto, Ontario M5G 2C1
like” domain, MALT1 is referred to as a mammalian para-Canada
caspase. However, attempts to demonstrate proteolytic2 Third Medical Department
activity for this protein have failed so far (Uren et al.,Technical University of Munich
2000), and the precise physiological role of MALT1 isKlinikum rechts der Isar
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Experiments in cell lines have shown that MALT1 can81675 Munich
associate directly with BCL10 (Lucas et al., 2001; Uren etGermany
al., 2000). The BCL10 gene was also originally identified
from a recurrent chromosomal translocation breakpoint
(t(1;14)(p22;q32)) in human MALT lymphomas. The BCL10Summary
protein possesses a caspase recruitment domain (CARD),
and its binding to MALT1 is mediated by associationThe translocation t(11;18)(q21;q21) involving MALT1 is
with the Ig-like and death domains of the paracaspasethe most common chromosomal abnormality in lym-
(Lucas et al., 2001; Uren et al., 2000).phomas of mucosa-associated lymphoid tissue. Al-
Studies in Bcl10-deficient mice have shown that Bcl10though the paracaspase MALT1 can bind to BCL10,
acts as a central regulator of T cell receptor (TCR)- andthe physiological function of MALT1 is unknown. Using
B cell receptor (BCR)-mediated lymphocyte activationmouse models, we show that Malt1 is essential for
but also plays an additional role during neural tube clo-T cell activation, proliferation, and IL-2 production in
sure (Ruland et al., 2001). In lymphocytes, Bcl10 trans-response to TCR ligation and strictly required for sig-
duces signals downstream of antigen receptor ligationnal-specific NF-B activation induced by the TCR but
and protein kinase C (PKC) activation that mediatenot TNF- or IL-1 signaling. Malt1 operates down-
NF-B induction (McAllister-Lucas et al., 2001; Rulandstream of Bcl10, controls the catalytic activity of the
et al., 2001). A family of five proteins that form homo- andcanonical IKK complex, and regulates the signaling of
heterodimeric transcription factors constitutes NF-B inJnk and p38 MAP kinases. In contrast to Bcl10 disrup-
mammals (Li and Verma, 2002). In lymphocytes, NF-Btion, however, inactivation of Malt1 has only mild ef-
activation leads primarily to cellular activation, prolifera-fects on B cell activation and does not cause defects
tion, survival, and induction of effector functions. NF-Bduring neurodevelopment. Thus, Malt1 is an essential
is tightly controlled by a collection of IB inhibitory pro-regulator of Bcl10 signaling that is differentially re-
teins that retain NF-B in an inactive form in the cyto-quired depending on cellular context.
plasm. Activation of NF-B is induced primarily by the
IB kinase (IKK) complex that contains the two catalyticIntroduction
subunits, IKK and IKK, and the regulatory subunit,
IKK. In response to a wide variety of extracellular stim-
Mucosa-associated lymphoid tissue (MALT) lymphomas
uli, IKK catalyzes the serine phosphorylation of IB pro-
are the most common lymphomas arising at extranodal teins which targets them for ubiquitin-mediated proteol-
sites. The majority of cases occur in the gastric mucosa ysis by the proteasome. This degradation frees NF-B
and are strongly associated with the presence of Helico- transcription factors to translocate to the nucleus where
bacter pylori (Zucca et al., 2000). Tumor growth initially they activate gene transcription. Parallel to this canoni-
depends on the presence of H. pylori as an antigen and cal mechanism of NF-B activation is an alternative,
thus can often be treated by simply eradicating H. pylori specialized pathway of NF-B induction that depends
with antibiotics. However, genetic alterations may ren- on selective activation of IKK and regulated proteolytic
der more advanced MALT lymphomas independent of processing of the NF-B2 precursor protein p100. p100
antigen. These tumors require more aggressive treat- has been shown to function as an NF-B inhibitor (Pom-
ment involving chemotherapeutics. erantz and Baltimore, 2002). This alternative pathway is
Several recurrent chromosomal abnormalities have activated mainly by certain TNF receptor superfamily
been identified in MALT lymphomas. By far the most members and is physiologically upregulated during B
common is translocation t(11;18)(q21;q21). Clinical stud- cell maturation.
ies have shown that t(11;18) positive lymphomas fail to We have previously shown that the adaptor protein
respond to antibiotic therapy (Liu et al., 2002; Sugiyama Bcl10 mediates NF-B activation by controlling the ac-
et al., 2001). Molecular cloning of the translocation break- tivity of the canonical IKK complex (Ruland et al., 2001).
Recent genetic experiments have demonstrated that the
Bcl10 binding protein Carma1/Card11/Bimp3 bridges*Correspondence: jruland@lrz.tu-muenchen.de
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antigen receptor proximal signaling and PKC activation development and that Bcl10 signaling during neurola-
tion is independent of Malt1.in both B and T cells to Jnk activation and to Bcl10-
mediated NF-B induction (Hara et al., 2003; Jun et al.,
Malt1 Is Required for In Vivo Immune Responses2003). However, the molecular events linking Bcl10 to
Because MALT1 is involved in the pathogenesis of hu-IKK activation are still unclear. Analyses of the cooverex-
man lymphomas, we focused our analysis on the rolepression of BCL10 and MALT1 in nonlymphoid cell lines
of Malt1 in the immune system. We first used flow cytom-have indicated that MALT1 is able to enhance BCL10-
etry to investigate whether Malt1 disruption affectedmediated NF-B induction, although overexpression of
lymphopoiesis. Normal numbers and differentiation ofwild-type (WT) MALT1 alone does not activate NF-B
B cell precursors were observed in the bone marrow of(Lucas et al., 2001; Uren et al., 2000). In contrast to
Malt1/ mice (data not shown). Whereas the expressionWT MALT1, the lymphoma-derived IAP2-MALT1 fusion
of surface IgM and IgD on mature splenic B cells wasproteins are themselves strong activators of NF-B (Lu-
comparable between WT and Malt1/ mice (Figure 2A),cas et al., 2001; Uren et al., 2000). Since an enforced
the mutants exhibited a reduction in the frequency ofoligomerization of the MALT1 paracaspase domain in-
marginal zone B cells (Figure 2B). Moreover, the CD5duces NF-B activity (Lucas et al., 2001), it has been
B1 cell population in the peritoneal cavity was drasticallysuggested that BCL10 might mediate oligomerization of
reduced in Malt1/ mice (Figure 2C). These findingsWT MALT1. In contrast, the IAP2-MALT1 fusion proteins
show that Malt1 is required for the efficient generation(which always contain an intact paracaspase domain)
or maintenance of marginal zone B cells and of B1 Bmight undergo autooligomerization resulting in constitu-
cells but is dispensable for the development of conven-tive signaling to NF-B (Lucas et al., 2001). It remains
tional B2 lymphocytes.to be determined whether MALT1 is involved in antigen
We next studied the development, differentiation, andreceptor signaling, at which molecular level MALT1
distribution of natural killer (NK) and T lineage cells. Themight interact with NF-B signaling, and whether MALT1
maturation of CD3IL-2R NK cells and CD3IL-2Rinfluences other signaling cascades.
NKT cells was unaffected by the absence of Malt1 sinceIn this study we show that targeted disruption of Malt1
cells of both lineages occurred at normal frequenciesin mice results in defective adaptive immune responses
in the livers of mutant mice (Figure 2D). Malt1/ micein vivo. Malt1 is strictly required for TCR-mediated cellu-
also had normal thymocyte numbers and displayed nor-lar proliferation, activation, and cytokine production, and
mal maturation of CD4CD8 double-positive thymo-for the development of marginal zone and B1 B cells.
cytes into CD4 and CD8 single-positive T cells (FigureIn T cells, Malt1 specifically mediates NF-B activation
2E). Neither did the deletion of Malt1 affect the totalvia signal-dependent control of catalytic IKK activity.
number or distribution of CD4 and CD8 T cell popula-Malt1 operates downstream of the TCR, PKC activation,
tions in the spleen or lymph nodes (Figure 2F and dataand Bcl10, and also controls Jnk and p38 MAP kinase
not shown). However, we consistently observed a de-signaling. However, in contrast to Bcl10, Malt1 is largely
crease in the frequency of activated T cells in the periph-dispensable for antigen receptor-mediated activation
ery of Malt1/ mice as detected by expression analysesof conventional B2 B cells and is not required during
of the cell surface markers CD25, CD44, and CD69 (dataembryonic development. Thus, the paracaspase Malt1
not shown). These data suggested that lymphocytemediates Bcl10 signaling to the canonical NF-B path-
function and activation might depend on the presenceway in a context-dependent manner.
of Malt1.
To study the functional capabilities of Malt1/ lym-
Results phocytes in vivo, we first measured basal serum Ig con-
centrations in nonimmunized mice by ELISA. All Ig iso-
Generation of Malt1-Deficient Mice types tested were found to be reduced in Malt1/ mice
To study the physiological role of Malt1 in vivo, we dis- compared to the WT (Figure 3A). To induce defined adap-
rupted exon 8 of the murine gene by homologous recom- tive immune responses, we injected Malt1/ and/ mice
bination in embryonic stem (ES) cells. Exon 8 encodes with the T cell-dependent antigen keyhole limpet haemo-
the N-terminal region of the paracaspase domain. ES cyanin (KLH) in complete Freund’s adjuvant (CFA) or the
cell lines heterozygous (/) for the mutation were used T cell-independent type II (TI-II) antigen tri-nitro-phenol-
to generate Malt1-deficient mice. Successful gene tar- (TNP)-Ficoll. As expected, WT mice synthesized KLH-
geting was confirmed by Southern blot analysis, and specific IgM immediately after immunization and showed
loss of Malt1 expression in homozygous Malt1-deficient a switch in Ig class to IgG production after 7 days (Figure
mice (Malt1/) was demonstrated by RT-PCR and 3B). In contrast to WT mice, Malt1/ mice failed com-
Western blotting (Figures 1A–1D). Malt1/ mice were pletely to produce measurable amounts of either KLH-
viable, fertile, and born at the expected Mendelian ratio specific IgM or IgG antibodies after immunization. More-
(Figure 1E). Since Malt1 was implicated in Bcl10 signal- over, IgM and IgG3 responses against TNP-Ficoll were
ing, and Bcl10 disruption leads to neural tube closure absent in Malt1/ mice for at least 21 days postimmuni-
defects in one-third of the mutant embryos (Ruland et zation (Figure 3C). These latter results are doubtless
al., 2001), we carefully inspected Malt1/ embryos at due to the lack of B1 cells and the reduction in marginal
different stages of gestation for gross developmental zone B cells in Malt1/mice. These cell types are essen-
abnormalities. However, in contrast to Bcl10/ em- tial mediators of TI-II responses (Martin and Kearney,
bryos, those lacking Malt1 did not show any obvious 2000; Martin et al., 2001). Our data thus clearly demon-
neuronal defects (data not shown). These results indi- strate that Malt1 is critical for the mounting of productive
immune responses in vivo.cate that Malt1 is dispensable for murine embryonic
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Figure 1. Generation of Malt1-Deficient Mice
(A) Gene targeting strategy. Top: A portion of
the WT murine Malt1 locus showing relevant
restriction sites. RV, EcoRV; X, XbaI; HIII,
HindIII. Exons 8 (E8) and 9 (E9) are shown as
open boxes. The position of the 3 flanking
probe (FP) is indicated. The structure of the
targeting vector (middle) and the mutant lo-
cus (bottom) are also shown.
(B) Southern blot analysis of tail DNA isolated
from WT (/), heterozygous (/), and Malt1-
deficient (/) mice. Genomic DNA was di-
gested with EcoRV and hybridized with the
flanking probe indicated in (A).
(C) Lack of Malt1 expression in Malt1/ mice.
Thymocyte RNA isolated from Malt1/ and /
mice was subjected to RT-PCR analysis us-
ing primer pairs specific for Malt1 or -actin.
(D) Western Blot analysis of splenic protein
lysates from of Malt1/, /, and / mice
using antibodies against Malt1.
(E) Total number and relative distribution (%)
of Malt1/, /, and / offspring derived
from heterozygous intercrosses.
Malt1 Is a Positive Regulator of T Cell Activation CD25, CD44, and CD69 was impaired in TCR-stimulated
Malt1/ T cells (Figure 4C). These results establish aTo define at a cellular level the immunodeficiency in-
duced by Malt1 disruption, we studied T and B cell genetic basis for the conclusion that Malt1, like Bcl10,
is an essential regulator of antigen receptor- and CD28-activation in vitro. To this end, we isolated peripheral
lymphocytes from Malt1/ and WT littermates and stim- mediated T cell activation.
ulated these cells with polyclonal mitogens in culture.
Since Malt1 has been implicated in Bcl10 signaling, we Malt1 Regulates TCR/CD28-Mediated Signaling
Leading to NF-B Activationconducted parallel experiments with purified T and B
cells from Bcl10/ mice. This strategy allowed us to Although Malt1 has previously been shown to bind to
Bcl10 (Lucas et al., 2001; Uren et al., 2000), no biochemi-directly compare the requirements for Malt1 and Bcl10
in lymphocyte activation and signaling. cal studies on Malt1 function have been reported in
lymphocytes to date. To study signaling events down-We first investigated the cellular responses of purified
mature T lymphocytes. Experimental induction of TCR stream of TCR and CD28 ligation that are controlled by
Malt1, we stimulated purified Malt1/ T cells in vitro.signaling in WT T cells with anti-CD3 antibodies (with
or without anti-CD28 costimulation) resulted in vigorous TCR crosslinking resulted in normal tyrosine phosphory-
lation patterns (Figure 5A), normal activation of the mito-cell proliferation (Figure 4A) and robust IL-2 production
(Figure 4B). In contrast, Malt1/ or Bcl10/ T lympho- gen-activated protein kinases (MAPK) Erk1 and Erk2
(Figure 5B), and normal induction of the transcriptioncytes did not expand (Figure 4A) or synthesize IL-2 (Fig-
ure 4B and Ruland et al., 2001) in response to these factor AP-1 (Figure 5C). However, in the absence of
Malt1, NF-B DNA binding activity was not inducedstimuli. Even supplementation of exogenous IL-2 to
Malt1/ T cell cultures did not restore TCR/CD28-medi- above baseline by either anti-CD3/CD28 costimulation
or by PMA plus ionomycin treatment (Figure 5C). Theated proliferation (Figure 4A). Moreover, in contrast to
WT cells, but like those deficient for Bcl10, Malt1/ same result was obtained for Bcl10/ T cells, consistent
with our previous data (Figure 5C and Ruland et al.,T cells did not respond to stimulation with phorbol myris-
tate actetate (PMA) (Figure 4A). PMA is a stimulus which 2001). Thus, like Bcl10, Malt1 is essential for TCR-initi-
ated signal transduction leading to NF-B activation.bypasses TCR proximal signaling by direct PKC activa-
tion. In addition to defective proliferation and IL-2 pro- To investigate whether Malt1 was a universal or a
signal-specific regulator of NF-B activation, we stimu-duction, the upregulation of the activation markers
Immunity
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Figure 2. Flow Cytometric Analyses of Lym-
phocyte Populations in Malt1/ Mice
(A) Surface IgD and IgM expression on splenic
B cells from Malt1/ and / mice.
(B) Surface CD21 and CD23 expression on
B220-gated splenic B cells from Malt1/ and
/ mice. The percentage of marginal zone B
cells is indicated.
(C) Surface B220 and CD5 expression on peri-
toneal cavity B cells. The percentage of B1
cells is indicated.
(D) Frequency of CD3IL-2R NK cells and
CD3IL-2R NKT cells in the lymphoid com-
partment of the liver.
(E) Expression of CD4 and CD8 on thymo-
cytes.
(F) CD4 and CD8 expression on splenic T cells.
lated Malt1/ T cells and murine embryonic fibroblasts Lucas et al., 2001). When CARMA3 was overexpressed
in Bcl10/ MEFs, the absence of Bcl10 function com-(MEFs) with the proinflammatory cytokines TNF- and
IL-1. These stimuli led to the same degree of NF-B pletely blocked CARMA3-mediated NF-B activation
(Figure 5G), confirming that CARMA3 acts upstream ofactivation in the presence or absence of Malt1 (Figure
5D and data not shown), indicating that Malt1 regulates Bcl10. In contrast, overexpression of IAP2-MALT1 in-
duced NF-B activity to the same degree in the presenceNF-B induction in a signal-specific manner.
NF-B signaling in T cells is mediated mainly through or absence of Bcl10 (Figure 5G). These data indicate
that activated MALT1 does not require Bcl10 for NF-Bthe canonical pathway of IKK activation and subsequent
IB phosphorylation and degradation (Li and Verma, activation and suggest that Malt1 may act downstream
of Bcl10.2002). To identify whether and at what molecular level
Malt1 is involved in this pathway, we stimulated purified Recent genetic studies implicated the lymphocyte-
specific Carma family member Carma1 not only in NF-BMalt1/and WT T cells with PMA plus ionomycin. Again,
we did parallel assays with Bcl10/ T cells. In vitro activation but also in MAP kinase signaling (Hara et al.,
2003; Jun et al., 2003). We therefore investigated Jnkkinase assays using immunoprecipitated IKK and re-
combinant GST-IB fusion protein as the substrate and p38 MAP kinase activation in Malt1/ T cells using
phosphospecific antibodies (Figure 5H). Stimulation ofshowed that catalytic IKK activity was induced only in
WT cells and not in Malt1/ or Bcl10/ T lymphocytes WT T cells with PMA plus ionomycin resulted in rapid
phosphorylation of all three Jnk isoforms and p38. How-(Figure 5E). The protein levels of the IKK , , and 
subunits were identical in cells of all three genotypes ever, in contrast to Erk activation, Jnk activation was
markedly impaired in Malt1/ T cells. The baseline level(data not shown). In line with these assays, rapid serine
phosphorylation and subsequent degradation of IB of phosphorylated p38 was higher in Malt1/ than in
WT T cells, but we still could not detect any p38 activa-occurred in WT but not in Malt1/ or in Bcl10/ T cells
(Figure 5F). These data establish Malt1 as an upstream tion over this baseline after stimulation. Thus, Malt1 is
required for Jnk and p38 phosphorylation in responseregulator of IKK activity.
To get a sense of whether Malt1 operated upstream to T cell activation.
or downstream of its binding partner Bcl10, we used a
surrogate system involving the overexpression of active Malt1/ Is Largely Dispensable for BCR-Mediated
NF-B ActivationIAP2-MALT1 fusion proteins (Lucas et al., 2001) and a
B site-containing luciferase reporter plasmid in WT and Bcl10 is not only essential for the activation of T cells
but also plays an analogous role in B cells. To investigateBcl10/ MEFs (Figure 5E). Parallel experiments were
performed with plasmids expressing CARMA3/CARD10/ the role of Malt1 in B cell activation, we purified splenic
B cells from Malt1/, Bcl10/, and WT mice and stimu-BIMP1, another binding partner of Bcl10 (McAllister-
Regulation of Antigen Receptor Signaling by Malt1
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cells, we observed a robust induction of NF-B DNA
binding activity in Malt1/ B cells. In line with these
results and with the proliferation data, IgM crosslinking
induced significant degradation of IB in Malt1/ B
cells but not in Bcl10/ B cells (Figure 6C). Together
these findings indicate that Malt1 is largely dispensable
for BCR-mediated signaling leading to NF-B activation
and is at least partially expendable for Bcl10 signaling
during B cell activation.
Discussion
The results presented in this report demonstrate that
Malt1 acts as an essential regulator of adaptive immune
responses in vivo, and that Malt1 is critically required for
functional T cell activation, proliferation, and cytokine
production. In addition, Malt1 is required for B1 and
marginal zone B cell development. The Malt1 molecule
is not merely an enhancer of Bcl10 signaling but is an
essential component of the Bcl10 signal transduction
complex. In T cells, Malt1 participates in the signal-
specific transduction pathway that mediates NF-B
activation downstream of TCR and CD28 engagement.
Previous experiments in mouse models with genetic
deletions of the NF-B subunits c-Rel or RelA (Doi et
al., 1997; Kontgen et al., 1995) have shown that NF-B
activity is necessary for T cell-mediated immune re-
sponses but dispensable for T lineage development.
Furthermore, studies of mice with targeted disruptions
of signaling molecules that mediate NF-B activationFigure 3. Immunodeficiency in Malt1/ Mice
in response to TCR/CD28 signaling, including PKC	,(A) Reduced basal immunoglobulin titers. Concentrations of Ig iso-
Carma1, Bcl10, and IKK (Hara et al., 2003; Jun et al.,types were determined in the sera of nonimmunized 8-week-old
2003; Ruland et al., 2001; Senftleben et al., 2001; SunWT (/, open circles) or Malt1-deficient (/, filled circles) mice
by ELISA. et al., 2000), have demonstrated that the integrity of this
(B) Impaired T cell-dependent antibody responses. WT (open sym- signal transduction cascade is necessary for functional
bols) and Malt1/ (closed symbols) mice were immunized with KLH T cell activation. Our analysis of the phenotype of Malt1-
in CFA. KLH-specific IgM and IgG1 production was determined by
deficient mice extends these results and genetically es-ELISA at 7, 14, 21, and 28 days after immunization.
tablishes Malt1 as an essential element of this pathway.(C) Impaired T cell-independent type II antibody responses. WT
The TCR recognizes antigen in the context of MHC(open symbols) and Malt1/ (closed symbols) mice were immunized
with TNP-Ficoll, and TNP-specific IgM and IgG3 production was molecules on antigen-presenting cells (APCs), inducing
determined at 7, 14, and 21 days after immunization. For (B) and the formation of a supramolecular activation cluster
(C), results from two (of six) representative mice are shown per ge- (SMAC) at the interface of the T cell and the APC (Dustin,
notype.
2002). Downstream signaling leading to NF-B activa-
tion is initiated following recruitment of PKC	 into the
SMAC and subsequent PKC	 activation (Isakov and Alt-lated these lymphocytes with anti-IgM ligation or anti-
IgM plus anti-CD40 crosslinking. We also carried out man, 2002). Activated PKC	 transduces downstream
signals through both Bcl10 and Carma1 (Gaide et al.,parallel experiments in which the B cells were stimulated
for 48 hr via engagement of Toll-like receptor 4 (TLR4) 2002; Hara et al., 2003; Jun et al., 2003; Pomerantz et
al., 2002; Ruland et al., 2001; Senftleben et al., 2001;by bacterial lipopolysaccharide (LPS) (Beutler, 2000). As
previously shown, Bcl10/ B cells did not expand in Wang et al., 2002). Direct pharmacological activation of
PKC isoforms with phorbol esters does not rescue theresponse to BCR stimulation (Figure 6A, left, and Ruland
et al., 2001). Surprisingly, however, Malt1/ B cells activation defects observed in Bcl10/ or Carma1/
T cells (Gaide et al., 2002; Hara et al., 2003; Jun etshowed only a mild defect and achieved about 80% of
WT proliferation, indicating that Malt1 is largely dispens- al., 2003; Pomerantz et al., 2002; Ruland et al., 2001;
Senftleben et al., 2001; Wang et al., 2002). Our findingable for BCR-mediated proliferation. Neither Bcl10 nor
Malt1 was required for LPS-stimulated B cell prolifera- that phorbol ester treatment did not restore NF-B acti-
vation or proliferative responses in Malt1/ T cells im-tion (Figure 6A, right).
We next examined BCR signaling in Malt1/ B cells. plies that the paracaspase Malt1, like its binding partner
Bcl10, is also a downstream effector of PKC activationWe found that overall tyrosine phosphorylation patterns
induced by BCR crosslinking were identical in WT, in T cell signaling.
The Bcl10 binding protein Carma1 functionally cou-Malt1/, and Bcl10/ B cells (data not shown) as was
the activation of AP-1 (Figure 6B). However, in contrast ples PKC	 activation to Bcl10-mediated NF-B induc-
tion (Gaide et al., 2002; Hara et al., 2003; Jun et al., 2003;to the defective BCR signaling to NF-B in Bcl10/ B
Immunity
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Figure 4. Defective T Cell Activation in
Malt1/ Mice
(A) Impaired proliferative responses. T cells
were purified from WT, Malt1/, and Bcl10/
mice and stimulated in vitro with medium
alone, soluble anti ()-CD3 (1 
g/ml), anti-
CD3 plus anti-CD28 (1 
g/ml), anti-CD3 plus
anti-CD28 plus IL-2 (50 U/ml), or PMA (10 ng/
ml) for 48 hr. Proliferation was determined by
[3H]thymidine incorporation.
(B) Impaired IL-2 production. IL-2 levels were
evaluated in the supernatants of Malt1/
or / T cell cultures stimulated with medium
alone (med) or anti-CD3 plus anti-CD28 (100
ng/ml each). n.d., not detectable.
(C) Activation markers. Flow cytometric anal-
ysis of CD25, CD44, and CD69 expression 24
hr after stimulation of Malt1/ or / T cells
with medium alone (control) or anti-CD3 plus
anti-CD28 (100 ng/ml each) in vitro.
Pomerantz et al., 2002; Wang et al., 2002). Bcl10 in turn IKK activation directly or indirectly. It is also important
to note that, like Carma1 disruption (Hara et al., 2003;can bind to Malt1 and induce oligomerization of this
paracaspase (Lucas et al., 2001). It was originally sug- Jun et al., 2003), deletion of Malt1 affects the Jnk and
p38 pathways as well as the NF-B pathway. The func-gested that the lymphoma-derived IAP2-MALT1 fusion
proteins might represent gain-of-function mutants able tional defects in Malt1/ lymphocytes are thus the con-
sequences of more than just defective NF-B activation.to oligomerize independently of Bcl10 to induce down-
stream signaling. Until now, there was no experimental Additional studies are required to identify the various
signaling elements operating downstream of Malt1 andconfirmation of this hypothesis. Our finding that IAP2-
MALT1 activates NF-B in Bcl10/ cells demonstrates their importance and contributions to lymphocyte biology.
In view of our results in Malt1/ T lymphocytes, andthat this fusion protein is able to signal in the absence
of Bcl10, indirectly suggesting that WT MALT1 signals the central and symmetrical role of Bcl10 and its binding
partner Carma1 in antigen receptor signaling to NF-Bdownstream of the Bcl10 adaptor protein.
Since Malt1 has structural similarities to the caspase in both mature T and B cells, it was surprising to find
that Malt1 was largely dispensable for BCR signalingfamily of cysteine proteases, we initially speculated that
Malt1 might be involved in the alternative pathway of in conventional B2 cells. These cells were still able to
activate NF-B after antigen receptor ligation (albeit atNF-B activation that is based on regulated proteolysis
of the NF-B2 p100 protein (Pomerantz and Baltimore, reduced levels), and we consistently observed substan-
tial B cell proliferation after BCR crosslinking. It is known2002). However, Malt1/ T cells exhibited WT amounts
of the p100 cleavage product p52 (data not shown). that the molecular elements upstream of Bcl10 that cou-
ple antigen recognition to Bcl10-mediated NF-B induc-These results indicate that Malt1 is unlikely to be re-
quired for the regulation of p100 processing. Rather, tion are distinct in B and T lymphocytes. The TCR and
the BCR utilize lineage-specific adaptor molecules andour data strongly show that Malt1 is necessary for the
induction of catalytic IKK activity and for IBphosphor- protein kinases to initiate signal transduction at the
membrane and distinct PKC isoforms to transduce prox-ylation and degradation in response to T cell signaling.
Our study therefore identifies Malt1 as an essential ele- imal signals to NF-B (Sedwick and Altman, 2002; Su
et al., 2002; Sun et al., 2000). The Bcl10 protein seemsment of the canonical NF-B pathway and suggests
that Malt1 functions upstream of the IKK complex. The to be a point of convergence that connects PKC signal-
ing to NF-B activation in both T and B cells. Our studyprecise biochemical mechanism by which Malt1 acti-
vates IKK remains unclear. If Malt1 indeed possesses now shows that the pathway diverges again in T and B
lymphocytes downstream of Bcl10. We propose a modelproteolytic activity as suggested by Uren et al., it is
possible that Malt1 cleaves a substrate to produce a (Figure 7) in which mature T cells depend entirely on
Malt1 to send information from Bcl10 to NF-B, whereasfactor that activates IKK. Alternatively, Malt1 could po-
tentially act as a scaffolding protein that assembles mature splenic B2 cells primarily utilize a still uncharac-
terized alternative mechanism. In addition, our findingshigher order signaling complexes following TCR and
CD28 ligation. In addition to its paracaspase domain, imply a specialized role for Malt1 in B1 and marginal
zone B cells, since both these populations are substan-Malt1 contains several protein-protein interaction motifs
that might allow it to recruit additional signaling mole- tially decreased in Malt1/ mice. The lack of B1 cells
is also reflected in the drastic reduction in serum levelscules like adaptor proteins or kinases that could mediate
Regulation of Antigen Receptor Signaling by Malt1
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Figure 5. Signal Transduction from the TCR
to NF-B in Malt1/ Mice
(A) Normal overall tyrosine phosphorylation
pattern in Malt/ T cells. Malt1/ and /
lymph node T cells were treated with hamster
anti-CD3 antibody (10 
g/ml) followed by
crosslinking with anti-hamster antibody (1
g/
ml) for the indicated times in minutes. Protein
lysates were subjected to Western blotting
using antibodies against phospho-tyrosine.
(B) Normal Erk activation. T cells were stimu-
lated as in (A), and protein lysates were sub-
jected to Western blotting using antibodies
specific for phospho-Erk.
(C) Impaired TCR/CD28- and PMA-induced
NF-B activation. Purified WT, Malt1/, and
Bcl10/ T cells were incubated with medium
alone (control), anti-CD3 (10 
g/ml) plus anti-
CD28 (1 
g/ml), or PMA (50 ng/ml) plus iono-
mycin (10 ng/ml). After 8 hr, nuclear extracts
were prepared and subjected to gel mobil-
ity shift assays with radiolabeled probes
containing NF-B or AP-1 binding site se-
quences.
(D) Normal TNF--induced NF-B activation.
WT or Malt1/ T cells were stimulated for 30
min with 10 ng/ml TNF-. Nuclear extracts
were subjected to gel mobility shift analysis
with probes containing NF-B binding site se-
quences.
(E) Defective IKK activation. WT, Malt1/,
and Bcl10/ T cells were stimulated with
PMA plus ionomycin for the indicated time in
minutes. The IKK complex was immunopre-
cipitated and IKK activity was determined in
vitro using GST-IB as a substrate.
(F) Defective IB phosphorylation and deg-
radation. After stimulation of WT, Malt1/,
and Bcl10/ T cells with PMA plus ionomycin
for the indicated time in minutes, phosphory-
lation and degradation of IB was investi-
gated by Western blotting using anti-phos-
pho-IB (P-IB), anti-IB, and anti-actin
(loading control) antibodies.
(G) CARMA3- and IAP2-MALT1-induced NF-
B activation in Bcl10/ cells. Bcl10/ or
/ MEFs were cotransfected with a NF-B
reporter plasmid plus either the empty
pcDNA3 vector (control), pcDNA3-Flag-IAP2-
MALT1, or pcDNA3-CARMA3-HA. After 48 hr,
NF-B activation was determined as de-
scribed in the Experimental Procedures.
(H) Defective Jnk and p38 MAP kinase signal-
ing in Malt1/ T cells. Purified T cells were stimulated with PMA plus ionomycin for the indicated time in minutes. Protein lysates were
subjected to Western blotting using antibodies against phospho-Jnk, Jnk, phospho-p38, p38, or actin (loading control).
of IgM and IgG3 (which are largely produced by these signaling pathway. Carma1/ mice exhibit impaired de-
velopment of the NK lineage (Hara et al., 2003), whereasparticular B lineage cells; Tarakhovsky, 1997), and the
defective immune responses to TI-II antigen. It is known normal development of both NK and NKT cells occurs
in Malt1/ mice. In addition, Carma1/ B cells showthat B1 B cells and marginal zone B cells differ from
conventional splenic B2 B cells not only in their location defects in LPS signaling (Hara et al., 2003), a pathway
which does not require either Malt1 or Bcl10 (Figureand surface marker expression but also in their BCR
repertoire and their requirement for signaling molecules 6A and Ruland et al., 2001). These findings collectively
reinforce the idea that individual cell lineages assembledownstream of the BCR (Martin and Kearney, 2000;
Tarakhovsky, 1997). Our results thus show that the utili- the Carma1/Bcl10/Malt1 signaling module in a context-
dependent manner.zation of Malt1 in Bcl10 signaling depends on cellular
context. This conclusion is also supported by the ob- The human MALT1 gene was initially identified through
study of chromosomal translocation breakpoints inservation that Malt1, unlike Bcl10, is expendable for
neurodevelopment (Ruland et al., 2001). The importance MALT lymphomas. These tumors originate from normal
marginal zone B cells (Wotherspoon et al., 2002). Inof cellular context extends to other molecules in the
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Figure 6. B Cell Activation and BCR-Mediated NF-B and AP-1 Activation in Malt1/ B Cells
(A) Proliferative response. Purified WT, Malt1/, and Bcl10/ splenic B cells were stimulated for 48 hr with medium alone, anti-IgM (10 
g/
ml), anti-IgM (10 
g/ml) plus anti-CD40 (5 
g/ml), or LPS (20 
g/ml), and B cell proliferation was assessed by [3H]thymidine incorporation.
(B) NF-B and AP-1 activation. WT, Malt1/, and Bcl10/ B cells were incubated for 8 hr with medium alone (control) or anti-IgM (5 
g/ml).
Nuclear extracts were prepared and subjected to gel mobility shift assays using probes containing NF-B or AP-1 binding site sequences.
(C) IB degradation induced by BCR signaling. Purified WT, Malt1/, and Bcl10/ B cells were stimulated with anti-IgM (5
g/ml). Degradation
of IB was determined by Western blotting using anti-IB and anti-actin (loading control) antibodies.
this study, we show that Malt1 is crucial for the normal aberrant MALT1 signaling in these cells could provide
a plausible molecular basis for MALT lymphoma devel-development and/or survival of marginal zone B cells.
A deregulation of MALT1 via translocation that leads to opment. It has already been suggested that MALT1 may
serve as an attractive drug target for the treatment of
these tumors (Uren et al., 2000). Since the disruption of
Malt1 in mice seems to mainly affect lymphoid cells,
such a treatment would be expected to have limited
side effects in vivo.
Experimental Procedures
Generation of Malt1-Deficient Mice
A genomic Malt1 clone was isolated from a 129/J library and used
to construct a targeting vector (Figure 1) that was electroporated into
E14K ES cells. Homologous recombinants were used to generate
chimeric mice and Malt1/ mice as described (Ruland et al., 2001).
Germline transmission was confirmed by PCR and Southern blot
analysis of tail DNA. Malt1/ mice were intercrossed to generate
Figure 7. A Model for the Differential Requirement of MALT1 in TCR homozygous Malt1/ animals. All animals were housed and main-
versus BCR Signal Transduction Leading to NF-B Activation tained in accordance with the protocols of the Ontario Cancer Insti-
tute Animal Care Committee.See text for details.
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